APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

FIC Dual-target Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FIC Dual-target Drugs Market Outlook and Growth Opportunities 2026

Report ID 173991810429 December 2025205 pages

Choose your research edition.

Industry ResearchFIC Dual-target Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Dual-target Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FIC Dual-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Dual-target Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Dual-target Drugs Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global FIC Dual-target Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FIC Dual-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FIC Dual-target Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FIC Dual-target Drugs market include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FIC Dual-target Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FIC Dual-target Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FIC Dual-target Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FIC Dual-target Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

FIC Dual-target Drugs Segment by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Dual-target Drugs Segment by Type

Polθ/PARP Targets

GPX4/CDK Targets

EZH2/HSP90 Targets

Others

FIC Dual-target Drugs Segment by Application

Hospital

Clinic

Other

FIC Dual-target Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global FIC Dual-target Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions FIC Dual-target Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FIC Dual-target Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze FIC Dual-target Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Dual-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Dual-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Dual-target Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Dual-target Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FIC Dual-target Drugs industry.

Chapter 3: Detailed analysis of FIC Dual-target Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of FIC Dual-target Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of FIC Dual-target Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FIC Dual-target Drugs Industry Trends Table 2. FIC Dual-target Drugs Industry Drivers Table 3. FIC Dual-target Drugs Industry Opportunities and Challenges Table 4. FIC Dual-target Drugs Industry Restraints Table 5. Global FIC Dual-target Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FIC Dual-target Drugs Revenue Share by Company (2021-2026) Table 7. Global FIC Dual-target Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global FIC Dual-target Drugs Sales Volume Share by Company (2021-2026) Table 9. Global FIC Dual-target Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global FIC Dual-target Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global FIC Dual-target Drugs Key Company Manufacturing Base & Headquarters Table 12. Global FIC Dual-target Drugs Company, Product Type & Application Table 13. Global FIC Dual-target Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global FIC Dual-target Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Polθ/PARP Targets Table 18. Significant Companies of GPX4/CDK Targets Table 19. Significant Companies of EZH2/HSP90 Targets Table 20. Significant Companies of Others Table 21. Global FIC Dual-target Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global FIC Dual-target Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global FIC Dual-target Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global FIC Dual-target Drugs Sales Volume Share by Type (2021-2026) Table 25. Global FIC Dual-target Drugs Sales Volume Share by Type (2027-2032) Table 26. Global FIC Dual-target Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global FIC Dual-target Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global FIC Dual-target Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global FIC Dual-target Drugs Sales Value Share by Type (2021-2026) Table 30. Global FIC Dual-target Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Other Table 34. Global FIC Dual-target Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global FIC Dual-target Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global FIC Dual-target Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global FIC Dual-target Drugs Sales Volume Share by Application (2021-2026) Table 38. Global FIC Dual-target Drugs Sales Volume Share by Application (2027-2032) Table 39. Global FIC Dual-target Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global FIC Dual-target Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global FIC Dual-target Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global FIC Dual-target Drugs Sales Value Share by Application (2021-2026) Table 43. Global FIC Dual-target Drugs Sales Value Share by Application (2027-2032) Table 44. Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global FIC Dual-target Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global FIC Dual-target Drugs Sales Market Share by Region (2021-2026) Table 47. Global FIC Dual-target Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global FIC Dual-target Drugs Sales Market Share by Region (2027-2032) Table 49. Global FIC Dual-target Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global FIC Dual-target Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global FIC Dual-target Drugs Sales Value Share by Region (2021-2026) Table 52. Global FIC Dual-target Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global FIC Dual-target Drugs Sales Value Share by Region (2027-2032) Table 54. Global FIC Dual-target Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global FIC Dual-target Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global FIC Dual-target Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global FIC Dual-target Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global FIC Dual-target Drugs Sales Market Share by Country (2021-2026) Table 60. Global FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global FIC Dual-target Drugs Sales Market Share by Country (2027-2032) Table 62. Global FIC Dual-target Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global FIC Dual-target Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global FIC Dual-target Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global FIC Dual-target Drugs Sales Value Market Share by Country (2027-2032) Table 66. Agios Company Information Table 67. Agios Business Overview Table 68. Agios FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Agios FIC Dual-target Drugs Product Portfolio Table 70. Agios Recent Development Table 71. BMS Company Information Table 72. BMS Business Overview Table 73. BMS FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. BMS FIC Dual-target Drugs Product Portfolio Table 75. BMS Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Dermavant Sciences Company Information Table 82. Dermavant Sciences Business Overview Table 83. Dermavant Sciences FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Dermavant Sciences FIC Dual-target Drugs Product Portfolio Table 85. Dermavant Sciences Recent Development Table 86. Genentech Company Information Table 87. Genentech Business Overview Table 88. Genentech FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Genentech FIC Dual-target Drugs Product Portfolio Table 90. Genentech Recent Development Table 91. Gilead Company Information Table 92. Gilead Business Overview Table 93. Gilead FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Gilead FIC Dual-target Drugs Product Portfolio Table 95. Gilead Recent Development Table 96. Immunocore Company Information Table 97. Immunocore Business Overview Table 98. Immunocore FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Immunocore FIC Dual-target Drugs Product Portfolio Table 100. Immunocore Recent Development Table 101. ImmunoGen Company Information Table 102. ImmunoGen Business Overview Table 103. ImmunoGen FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ImmunoGen FIC Dual-target Drugs Product Portfolio Table 105. ImmunoGen Recent Development Table 106. Mallinckrodt Company Information Table 107. Mallinckrodt Business Overview Table 108. Mallinckrodt FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Mallinckrodt FIC Dual-target Drugs Product Portfolio Table 110. Mallinckrodt Recent Development Table 111. Marinus Company Information Table 112. Marinus Business Overview Table 113. Marinus FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Marinus FIC Dual-target Drugs Product Portfolio Table 115. Marinus Recent Development Table 116. Phathom Company Information Table 117. Phathom Business Overview Table 118. Phathom FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Phathom FIC Dual-target Drugs Product Portfolio Table 120. Phathom Recent Development Table 121. Polarean lmaging Company Information Table 122. Polarean lmaging Business Overview Table 123. Polarean lmaging FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Polarean lmaging FIC Dual-target Drugs Product Portfolio Table 125. Polarean lmaging Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Pfizer FIC Dual-target Drugs Product Portfolio Table 130. Pfizer Recent Development Table 131. Eli Lilly Company Information Table 132. Eli Lilly Business Overview Table 133. Eli Lilly FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Eli Lilly FIC Dual-target Drugs Product Portfolio Table 135. Eli Lilly Recent Development Table 136. Roche Company Information Table 137. Roche Business Overview Table 138. Roche FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Roche FIC Dual-target Drugs Product Portfolio Table 140. Roche Recent Development Table 141. Merck Company Information Table 142. Merck Business Overview Table 143. Merck FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Merck FIC Dual-target Drugs Product Portfolio Table 145. Merck Recent Development Table 146. Novartis Company Information Table 147. Novartis Business Overview Table 148. Novartis FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Novartis FIC Dual-target Drugs Product Portfolio Table 150. Novartis Recent Development Table 151. Johnson & Johnson Company Information Table 152. Johnson & Johnson Business Overview Table 153. Johnson & Johnson FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Johnson & Johnson FIC Dual-target Drugs Product Portfolio Table 155. Johnson & Johnson Recent Development Table 156. Sanofi Company Information Table 157. Sanofi Business Overview Table 158. Sanofi FIC Dual-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Sanofi FIC Dual-target Drugs Product Portfolio Table 160. Sanofi Recent Development Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. FIC Dual-target Drugs Distributors List Table 164. FIC Dual-target Drugs Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. FIC Dual-target Drugs Product Image Figure 2. Global FIC Dual-target Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global FIC Dual-target Drugs Sales (2021-2032) & (K Units) Figure 5. Global FIC Dual-target Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global FIC Dual-target Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Polθ/PARP Targets Image Figure 10. GPX4/CDK Targets Image Figure 11. EZH2/HSP90 Targets Image Figure 12. Others Image Figure 13. Global FIC Dual-target Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global FIC Dual-target Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global FIC Dual-target Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global FIC Dual-target Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global FIC Dual-target Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global FIC Dual-target Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global FIC Dual-target Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global FIC Dual-target Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global FIC Dual-target Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global FIC Dual-target Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global FIC Dual-target Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global FIC Dual-target Drugs Sales Value Share by Application (2021-2032) Figure 28. Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global FIC Dual-target Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global FIC Dual-target Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global FIC Dual-target Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America FIC Dual-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe FIC Dual-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific FIC Dual-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America FIC Dual-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa FIC Dual-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa FIC Dual-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt FIC Dual-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. FIC Dual-target Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. FIC Dual-target Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Polθ/PARP Targets
  • GPX4/CDK Targets
  • EZH2/HSP90 Targets
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global FIC Dual-target Drugs Sales Value (2021-2032)
  4. 1.2.2 Global FIC Dual-target Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global FIC Dual-target Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 FIC Dual-target Drugs Market Dynamics
  1. 2.1 FIC Dual-target Drugs Industry Trends
  2. 2.2 FIC Dual-target Drugs Industry Drivers
  3. 2.3 FIC Dual-target Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Dual-target Drugs Industry Restraints
3 FIC Dual-target Drugs Market by Company
  1. 3.1 Global FIC Dual-target Drugs Company Revenue Ranking in 2025
  2. 3.2 Global FIC Dual-target Drugs Revenue by Company (2021-2026)
  3. 3.3 Global FIC Dual-target Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global FIC Dual-target Drugs Average Price by Company (2021-2026)
  5. 3.5 Global FIC Dual-target Drugs Company Ranking (2024-2026)
  6. 3.6 Global FIC Dual-target Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global FIC Dual-target Drugs Company Product Type and Application
  8. 3.8 Global FIC Dual-target Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global FIC Dual-target Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 FIC Dual-target Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 FIC Dual-target Drugs Market by Type
  1. 4.1 FIC Dual-target Drugs Type Introduction
  2. 4.1.1 Polθ/PARP Targets
  3. 4.1.2 GPX4/CDK Targets
  4. 4.1.3 EZH2/HSP90 Targets
  5. 4.1.4 Others
  6. 4.2 Global FIC Dual-target Drugs Sales Volume by Type
  7. 4.2.1 Global FIC Dual-target Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global FIC Dual-target Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global FIC Dual-target Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global FIC Dual-target Drugs Sales Value by Type
  11. 4.3.1 Global FIC Dual-target Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global FIC Dual-target Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global FIC Dual-target Drugs Sales Value Share by Type (2021-2032)
5 FIC Dual-target Drugs Market by Application
  1. 5.1 FIC Dual-target Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global FIC Dual-target Drugs Sales Volume by Application
  6. 5.2.1 Global FIC Dual-target Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Dual-target Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global FIC Dual-target Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global FIC Dual-target Drugs Sales Value by Application
  10. 5.3.1 Global FIC Dual-target Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FIC Dual-target Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global FIC Dual-target Drugs Sales Value Share by Application (2021-2032)
6 FIC Dual-target Drugs Regional Sales and Value Analysis
  1. 6.1 Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FIC Dual-target Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global FIC Dual-target Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global FIC Dual-target Drugs Sales by Region (2027-2032)
  5. 6.3 Global FIC Dual-target Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global FIC Dual-target Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global FIC Dual-target Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global FIC Dual-target Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global FIC Dual-target Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America FIC Dual-target Drugs Sales Value (2021-2032)
  12. 6.6.2 North America FIC Dual-target Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe FIC Dual-target Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe FIC Dual-target Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific FIC Dual-target Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific FIC Dual-target Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America FIC Dual-target Drugs Sales Value (2021-2032)
  21. 6.9.2 South America FIC Dual-target Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa FIC Dual-target Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa FIC Dual-target Drugs Sales Value Share by Country, 2025 VS 2032
7 FIC Dual-target Drugs Country-level Sales and Value Analysis
  1. 7.1 Global FIC Dual-target Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FIC Dual-target Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global FIC Dual-target Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global FIC Dual-target Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global FIC Dual-target Drugs Sales by Country (2027-2032)
  6. 7.4 Global FIC Dual-target Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global FIC Dual-target Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global FIC Dual-target Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt FIC Dual-target Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt FIC Dual-target Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt FIC Dual-target Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agios
  2. 8.1.1 Agios Company Information
  3. 8.1.2 Agios Business Overview
  4. 8.1.3 Agios FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Agios FIC Dual-target Drugs Product Portfolio
  6. 8.1.5 Agios Recent Developments
  7. 8.2 BMS
  8. 8.2.1 BMS Company Information
  9. 8.2.2 BMS Business Overview
  10. 8.2.3 BMS FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BMS FIC Dual-target Drugs Product Portfolio
  12. 8.2.5 BMS Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Dermavant Sciences
  20. 8.4.1 Dermavant Sciences Company Information
  21. 8.4.2 Dermavant Sciences Business Overview
  22. 8.4.3 Dermavant Sciences FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dermavant Sciences FIC Dual-target Drugs Product Portfolio
  24. 8.4.5 Dermavant Sciences Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Genentech FIC Dual-target Drugs Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Gilead
  32. 8.6.1 Gilead Company Information
  33. 8.6.2 Gilead Business Overview
  34. 8.6.3 Gilead FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Gilead FIC Dual-target Drugs Product Portfolio
  36. 8.6.5 Gilead Recent Developments
  37. 8.7 Immunocore
  38. 8.7.1 Immunocore Company Information
  39. 8.7.2 Immunocore Business Overview
  40. 8.7.3 Immunocore FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Immunocore FIC Dual-target Drugs Product Portfolio
  42. 8.7.5 Immunocore Recent Developments
  43. 8.8 ImmunoGen
  44. 8.8.1 ImmunoGen Company Information
  45. 8.8.2 ImmunoGen Business Overview
  46. 8.8.3 ImmunoGen FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoGen FIC Dual-target Drugs Product Portfolio
  48. 8.8.5 ImmunoGen Recent Developments
  49. 8.9 Mallinckrodt
  50. 8.9.1 Mallinckrodt Company Information
  51. 8.9.2 Mallinckrodt Business Overview
  52. 8.9.3 Mallinckrodt FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt FIC Dual-target Drugs Product Portfolio
  54. 8.9.5 Mallinckrodt Recent Developments
  55. 8.10 Marinus
  56. 8.10.1 Marinus Company Information
  57. 8.10.2 Marinus Business Overview
  58. 8.10.3 Marinus FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Marinus FIC Dual-target Drugs Product Portfolio
  60. 8.10.5 Marinus Recent Developments
  61. 8.11 Phathom
  62. 8.11.1 Phathom Company Information
  63. 8.11.2 Phathom Business Overview
  64. 8.11.3 Phathom FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Phathom FIC Dual-target Drugs Product Portfolio
  66. 8.11.5 Phathom Recent Developments
  67. 8.12 Polarean lmaging
  68. 8.12.1 Polarean lmaging Company Information
  69. 8.12.2 Polarean lmaging Business Overview
  70. 8.12.3 Polarean lmaging FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Polarean lmaging FIC Dual-target Drugs Product Portfolio
  72. 8.12.5 Polarean lmaging Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer FIC Dual-target Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Eli Lilly
  80. 8.14.1 Eli Lilly Company Information
  81. 8.14.2 Eli Lilly Business Overview
  82. 8.14.3 Eli Lilly FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly FIC Dual-target Drugs Product Portfolio
  84. 8.14.5 Eli Lilly Recent Developments
  85. 8.15 Roche
  86. 8.15.1 Roche Company Information
  87. 8.15.2 Roche Business Overview
  88. 8.15.3 Roche FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Roche FIC Dual-target Drugs Product Portfolio
  90. 8.15.5 Roche Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Merck FIC Dual-target Drugs Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Novartis FIC Dual-target Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson FIC Dual-target Drugs Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi FIC Dual-target Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi FIC Dual-target Drugs Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FIC Dual-target Drugs Value Chain Analysis
  2. 9.1.1 FIC Dual-target Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FIC Dual-target Drugs Sales Mode & Process
  6. 9.2 FIC Dual-target Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FIC Dual-target Drugs Distributors
  9. 9.2.3 FIC Dual-target Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst